Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Jasmine I CaulfieldLilach AizenbudAna Luisa PerdigotoEric MeffreLucia JilaveanuDominika A MichalekStephen S RichYariv AizenbudAdebowale AdeniranKevan C HeroldMatthew R AustinHarriet M KlugerPublished in: Journal for immunotherapy of cancer (2023)
mutation as a potential predictive biomarker is warranted, as it might improve patient selection for treatment regimens. Furthermore, this genetic alteration suggests potential mechanisms of islet cell destruction in the setting of checkpoint inhibitor therapy.
Keyphrases
- type diabetes
- glycemic control
- cardiovascular disease
- papillary thyroid
- dna damage
- single cell
- cell therapy
- cell cycle
- genome wide
- stem cells
- dna repair
- squamous cell carcinoma
- risk assessment
- mesenchymal stem cells
- metabolic syndrome
- gene expression
- dna methylation
- oxidative stress
- skeletal muscle
- young adults
- cell proliferation
- lymph node metastasis
- childhood cancer